![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: Chronic lymphocytic leukemia (CLL) is the most common leukemia. Over the last 40 years, the evolution of chemotherapeutic options and the addition of the anti-CD20 antibody rituximab have improved response rates significantly. Obinutuzumab, a next generation CD20 antibody, continues that evolution.
Areas covered: In this review, we discuss the pre-clinical and recent clinical experiences with obintuzumab and discuss its potential future role in the management of CLL as well as the interest in combining this next generation CD20 antibody with B-cell receptor pathway inhibitors. Obinutuzumab has a number of modifications that increase its efficacy relative to rituximab resulting in improved antibody-dependent cell-mediated cytotoxicity and direct cell death. These biological attributes have translated into improved clinical responses. The clinical superiority of obinutuzumab relative to rituximab is best demonstrated in the CLL11 trial. In this randomized Phase III trial, for patients requiring upfront CLL treatment, the combination of obinutuzumab and chlorambucil was found to result in improved response and progression-free survival relative to the combination of rituximab and chlorambucil.
Expert opinion: Obinutuzumab has clear pre-clinical and clinical superiority to rituximab and will be a central agent in the evolving management of CLL.
Declaration of interest
JR Brown is a consultant for Gilead, Pharmacyclics, Janssen, MorphoSys, Genentech/Roche, Emergent, GlaxoSmithKline and Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.